Insight

Katsuaki Maehara: Interesting indirect comparison analysis for Melanoma

Katsuaki Maehara/X

Aug 19, 2024, 11:57

Katsuaki Maehara: Interesting indirect comparison analysis for Melanoma

Katsuaki Maehara shared a post on X:

“Melanoma Journal of Clinical Oncology.

NCCN Guidelines recommended both Nivo+ Rela and Nico + Ipi as preferred, category 1, first-line systemic therapy options for unresectable or metastatic melanoma.
An interesting INDIRECT comparison analysis has been published.”

No difference in efficacy has been observed, but there are indications that Nivo + Rela tends to be better in terms of safety.

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

Authors: Georgina V. Long, Evan J. Lipson, F. Stephen Hodi, Paolo A. Ascierto, James Larkin, Christopher Lao, Jean-Jacques Grob, Flavia Ejzykowicz, Andriy Moshyk3, Viviana Garcia-Horton, Zheng-Yi Zhou, Yiqiao Xin, Jennell Palaia, Laura McDonald, Sarah Keidel, Anthony Salvatore, Divya Patel, Leon A. Sakkal, Hussein Tawbi, and Dirk Schadendorf.

Source: Katsuaki Maehara/X

cancer Dirk Schadendorf eorgina V. Long Evan J Lipson F. Stephen Hodi Hussein Tawbi Journal of Clinical Oncology Katsuaki Maehara Leon A. Sakkal NCCN guidelines OncoDaily Oncology

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage